
Loading, please wait...

Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
— Hippocrates

Researchers have recently developed a novel cascade nanozyme inflammation therapy to address the persistent challenges of reactive oxygen species (ROS) in inflammatory diseases. Chronic inflammation typically leads to high ROS levels. These molecules cause irreversible damage by destroying nucleic acids, proteins, and lipids. Consequently, effectively eliminating excess ROS remains a crucial step in modern medicine. This study introduces a sophisticated platform using ferrihydrite (Fh) and oxidative carbon dots (C-dots) to mimic natural enzyme properties.
The research team synthesized Fh using an innovative copper oxide (CuO)-promoted ferric iron hydrolysis method. This specific approach successfully addressed product sensitivity issues seen in previous manufacturing techniques. Furthermore, the scientists combined these Fh particles with oxidative carbon dot nanozymes through electrostatic and coordination interactions. This process resulted in a stable cascade nanozyme, designated as Fh@C-dot. Additionally, characterization results confirmed that the binding process was highly efficient. Therefore, the composite material retains the unique strengths of both individual components.
During the evaluation, the Fh@C-dot composite demonstrated remarkable catalytic performance. Specifically, Fh exhibited strong catalase (CAT)-like activity. Meanwhile, the C-dots showed excellent superoxide dismutase (SOD)-like activity and hydroxyl radical scavenging capabilities. Moreover, the integrated Fh@C-dot platform possessed both radical scavenging properties and enhanced CAT-like activity. In addition to its chemical efficacy, the platform showed exceptional biosafety. Specifically, in vivo tests on mice confirmed significant therapeutic effects on irritant contact dermatitis. Consequently, this innovation provides a potential alternative to traditional natural antioxidants for treating localized skin inflammation.
The Fh@C-dot nanozyme offers a dual-action approach. It provides both CAT-like and SOD-like activities to scavenge multiple types of reactive oxygen species effectively. Its enhanced radical scavenging ability makes it more potent than individual nanozymes.
The platform targets the oxidative stress at the site of inflammation. By eliminating excess ROS, it prevents cellular damage and reduces the inflammatory response in the skin tissue, as demonstrated in mice models.
Yes, the novel CuO-promoted ferric iron hydrolysis method reduces sensitivity to reaction parameters. This ensures a more consistent and higher quality production of ferrihydrite for medical applications.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional diagnosis. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References

Researchers developed Fh@C-dot, a cascade nanozyme platform that scavenges reactive oxygen species to treat inflammation and irritant contact dermatitis....
last month

A review of SREBPs as key regulators of lipid synthesis in cancer and their potential as targets for precision medicine in oncology and metabolic disorders....
Today

IPA, a gut-derived metabolite, suppresses PPARγ to prevent bone loss and marrow fat accumulation, offering a potential therapeutic strategy for osteoporosis...
Today

A review of experimental rodent models for Cardiorenal Syndrome types 3 and 4, exploring the pathophysiology and limitations of current research models....
Today

A new study identifies H3K18la as a key metabolic-epigenetic link in osteoarthritis, offering a novel therapeutic target to prevent subchondral bone loss....
Today

A study reveals that blue light exposure during sleep (LEDS) is linked to hyperglycemia and worse psychosocial outcomes in adults with Type 1 Diabetes....
Today